



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/APTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/534,773
		Filing Date	May 13, 2005
		First Named Inventor	Robertson
		Group Art Unit	1643
		Examiner Name	Lynn Anne Bristol
Sheet 1	of 5	Attorney Docket Number	49409-0050 (315804)

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
LAB	1	US-4,898,951		Symons	02-06-1990	
	2	US-4,937,185		Webb et al.	06-26-1990	
	3	US-5,157,020		Kay et al.	10-20-1992	
	4	US-5,652,115		Marks et al.	07-26-1990	
	5	US-5,726,023		Cheever et al.	03-10-1998	
	6	US-5,876,728		Kass et al.	03-02-1999	
	7	US-6,322,989		Cohen	11-27-2001	
	8	US 20020168696		Hanash	11-14-2002	

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴				
LAB	9		EP 0 236 606	Imre Corporation	06-24-1992		
	10		JP 09 189702	Hitachi Chem Co. Ltd.	07-22-1997		
LAB	11		WO 92/13065	Novo Nordisk A/S	08-06-1992		
	12		WO 93/11236	Medical Research Council	06-10-1993		
	13		WO 93/21529	Marks et al.	10-1993		
	14		WO 94/23728	Northwestern University	10-27-1994		
	15		WO 96/00084	Torchilin et al.	01-04-1996		
	16		WO 96/03502 A2	Ramot University Authority for Applied Research and Industrial Development Ltd.	02-08-1996		
	17		WO 97/14794	Lane et al.	04-24-1997		
	18		WO 00/26668	The Regents of the University of Michigan	05-11-2000		

Examiner Signature	/Lynn Bristol/	Date Considered	03/27/2007
-----------------------	----------------	--------------------	------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/534,773
		Filing Date	May 13, 2005
		First Named Inventor	Robertson
		Group Art Unit	1643
		Examiner Name	Lynn Anne Bristol
Sheet 2	of 5	Attorney Docket Number	49409-0050 (315804)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
LAB	19*	APARECIDA et al., "Value of CEA Level Determination in Gallbladder Bile in the Diagnosis of Liver Metastases Secondary to Colorectal Adenocarcinoma", Sao Paulo Medical Journal, 2001, Volume 119, No. 3, pp. 110-113.	
	20*	APOSTOLOPOULOS et al., Nature Medicine, 1998, Vol. 4, pp. 315-320.	
	21*	BAECHSTROM, et al., "Purification and Characterization of Sialyl-Le - Carrying Mucins of Human Bile; Evidence for the Presence of MUC1 and MUC3 Apoproteins", The Journal of Biological Chemistry, 1994, Volume 269, No. 20, pp. 14430-14437.	
	22*	BEATTY, et al., "Biochemical Characterization of the Soluble Form of Tumor Antigen MUC1 Isolated from Sera and Ascites Fluid of Breast and Pancreatic Cancer Patients", Clinical Cancer Research, 2001, Vol. 7, pp. 781-787.	
	23*	BEN-MAHREZ et al., British Journal of Cancer, 1988.	
	24*	BHATTI et al.; Journal of Tumor Marker Oncology, Summer-1994, Vol. 9, pp. 125-131.	
	25*	CROCE et al.; Cancer. Immunol. Immunother., 1995, Vol. 40, pp. 132-137.	
	26*	DEGUCHI et al.; Int. Arch. Allergy Appl. Immunol., 1988, Vol. 87, pp. 313-316.	
	27*	DENTON et al.; Cancer Letters, 1993, Vol. 70, pp. 143-150.	
	28*	DISIS et al.; Journal of Clinical Oncology, 1997, Vol. 15, pp. 3363-3367.	
	29*	FISHMAN, P., "Application of autoantibodies to cancer therapy: A new concept", <i>The 9th International Congress of Immunology</i> , 1995, p. 664.	
	30*	GOUREVITCH, MM; "Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients"; <i>British Journal of Cancer</i> ; 72, pp. 934-938; (1995).	
	31*	GREEN et al.; European Journal of Cancer, 1994, Vol. 30A, pp. 580-584.	
	32*	GÜRE, "Human Lung Cancer Antigens Recognized by Autologous Antibodies Definition of a Novel cDNA Derived from the Tumor Suppressor Gene Locus on Chromosome 3p21.3", Ludwig Institute for Cancer Research, pp. 1034-1040	
	33*	Abstract of HAYES; Anticancer Drugs, 1995, Vol. 6, suppl. 2, pp. 26-27..	
	34*	HEHIR et al., Journal of Surgical Oncology, 1993, Vol. 54, pp. 207-210.	
	35*	HILL et al., "Nature of Carcinoembryonic Antigen Purified From Malignant Ascitic Fluid of Serous Cystadenocarcinoma of the Ovary", Molecular Immunology, 1981, Vol. 18, No. 7, pp. 647-653.	
	✓	36*	HINODA, et al., "Detection of a Circulating Antibody Against a Peptide Epitope on a Mucin Core Protein, MUC1, in Ulcerative Colitis", 1991, pp. 163-168.

Examiner Signature	/Lynn Bristol/	Date Considered	03/27/2007
--------------------	----------------	-----------------	------------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/534,773
		Filing Date	May 13, 2005
		First Named Inventor	Robertson
		Group Art Unit	1643
		Examiner Name	Lynn Anne Bristol
Sheet 3	of 5	Attorney Docket Number	49409-0050 (315804)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
LAB	37*	HOUGHTON et al.; "Detection of Cell Surface and Intracellular Antigens by Human Monoclonal Antibodies - Hybrid Cell Lines Derived from Lymphocytes of Patients with Malignant Melanoma"; <i>J. Exp. Med.</i> ; Vol. 158, July 1983; pp. 53-65.	
	38*	JANEWAY et al., <i>Immunobiology</i> , 5 th ed.	
	39*	KARANIKAS, et al. <i>J Clin Invest</i> 1997 December 1, Vol. 100, No. 11, pp. 2783-2792.	
	40*	KAWAHARA; <i>Cancer</i> , 1986, Vol. 58, pp. 2008-2012.	
	41*	KOTERA et al.; <i>Cancer Research</i> , 1994, Vol. 54, pp. 2856-2860.	
	42*	KURALAY, et al., "Diagnostic Usefulness of Tumour Marker Levels in Pleural Effusions of Malignant and Benign Origin, <i>Clinica Chimica Acta</i> , 2000, Vol. 300, pp. 43-55.	
	43*	KUTTEH, W.H., et al., "Immunologic characterization of tumor markers in human ovarian cancer cell lines"; <i>Journal of the Society for Gynecologic Investigation</i> , 1996, vol. 3, no. 4, pp. 216-222.	
	44*	LAENG, et al., "Anti-Neural Autoantibodies, types 1 and 2: Their Utility in the Study of Tumors of the Nervous System", <i>Acta Neuropathol</i> , 1998, Vol. 96, pp. 329-339.	
	45*	LAFOND, R.E., et al., "Autoantibodies to c-myc protein: elevated levels in patients with African Burkitt's lymphoma and normal Ghanians", <i>Autoimmunity</i> , vol. 13, no. 3, 1992, pp. 215-224.	
	46*	LAI, et al., "Presence of Serum Anti-P53 Antibodies is Associated with Pleural Effusions and Poor Prognosis in Lung Cancer Patients", <i>Clinical Cancer Research</i> , 1998, Vol. 4, pp. 3025-3030.	
	47*	LAWNICZAK, et al., "The Search for Tumor-Associated Proteins in Pleural Effusions by Means of Monoclonal Antibodies and a Dot Blot Assay", <i>Lung</i> , 1992, Vol. 170, pp. 65-74.	
	48*	MERCER, "Use of Multiple Markers to Enhance Clinical Utility", <i>Immunology Series</i> , Vol. 53, 1990, pp. 39-54.	
	49*	MONTENARH, et al., "P53 Autoantibodies in the Sera, Cyst and Ascitic Fluids of Patients with Ovarian Cancer", <i>International Journal of Oncology</i> , 1998, Vol. 13, pp. 605-610.	
	50*	NERY, et al., "Isolation and Partial Characterization of Macromolecular Urinary Aggregates Containing Carcinoembryonic Antigen-Like Activity", <i>Br J. Cancer</i> , 1974, Vol. 29, No. 413, pp. 303-314.	
	51*	NUSTAD et al., "Epitopes on CA 125 from Cervical Mucus and Ascites Fluid and Characterization of Six New Antibodies", pp. 303-314.	
↓	52*	Abstract of PANDHA et al.; <i>Cancer Gene Therapy</i> , 1997, Vol. 4, No. 5, page 310.	

Examiner Signature	/Lynn Bristol/	Date Considered	03/27/2007
--------------------	----------------	-----------------	------------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/534,773
		Filing Date	May 13, 2005
		First Named Inventor	Robertson
		Group Art Unit	1643
		Examiner Name	Lynn Anne Bristol
Sheet 4	of 5	Attorney Docket Number	49409-0050 (315804)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
LAB	53	PAVELIC et al., Anticancer Research, 1991, Vol. 11, pp. 1421-1428.	
	54	PETRARCA, C., "Human Antibodies Against the Polymorphic Epithelial Mucin in Ovarian Cancer Patients Recognise a Novel Sequence in the Tandem Repeat Region"; <i>European Journal of Cancer</i> , Vol. 32A, No. 12, pp. 2155-2163, 1996.	
	55	PETRAKOU et al.; International Journal of oncology, 1997, Vol. 11, suppl. Page 902.	
	56	RAO, S.G., "Detection of Human Ovarian Tumor Associated Antigens by Autologous Antibodies Isolated from Ovarian Carcinoma Ascites Fluid"; <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , 1987, vol. 28, p. 358.	
	57	RUSCIANO, "Concomitant Purification of Prostatic Carcinoma Tumor Markers from Human Seminal Fluid Under Nondenaturing Conditions", <i>Clinical Chemistry</i> , 1988, Vol. 34, No. 12, pp. 2528-2532.	
	58	SAHIN et al.; PNAS, 1995, Vol. 92, pp. 11810-11813	
	59	SANDRIN et al., Glycoconjugate Journal, 1997, Vol. 14, pp. 97-105.	
	60	SCANLAN et al.; International Journal of Cancer, 1998, Vol. 76, pp. 652-658	
	61	SCHNEIDER, J. "P53 Protein, EGF Receptor, and Anti-P53 Antibodies in Serum from Patients with Occupationally Derived Lung Cancer", <i>British Journal of Cancer</i> , 1999, Vol. 80, No. 12, pp. 1987-1994.	
	62	SHIBATA, et al., "Purification and Characterization of Prostate Specific Antigen from Human Urine", <i>Biochimica et Biophysica Acta</i> , 1997, Vol. 1336, pp. 425-433.	
	63	SOKOLOFF, et al., "A Dual-Monoclonal Sandwich Assay for Prostate-Specific Membrane Antigen: Levels in Tissues, Seminal Fluid and Urine", <i>The Prostate</i> , 2000, Vol. 43, pp. 150-157.	
	64	Abstract of STEARNS et al.; <i>Breast Cancer Research and Treatment</i> , 8 Feb. 1998, Vol. 52, pp. 239-259	
	65	STUBBS, et al., "Faecal Carcinoembryonic Antigen (CEA) in Patients with Large Bowel Cancer", <i>European Journal of Surgical Oncology</i> , 1987, Vol. 13, pp. 433-436.	
	66	TONDINI, et al., "Comparison of CA15-3 and Carcinoembryonic Antigen in Monitoring the Clinical Course of Patients with Metastatic Breast Cancer", <i>Cancer Research</i> , 1988, Vol. 48, No. 14, pp. 4107-4112.	
✓	67	TOTH, et al., "A Carcinoembryonic Antigen (CEA) Binding Protein From Ascites Influences CEA Uptake by Macrophages", 1990, Vol. 171, No. 2, pp. 633-640.	

Examiner Signature	/Lynn Bristol/	Date Considered	03/27/2007
--------------------	----------------	-----------------	------------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/534,773
		Filing Date	May 13, 2005
		First Named Inventor	Robertson
		Group Art Unit	1643
		Examiner Name	Lynn Anne Bristol
Sheet 5 of 5	Attorney Docket Number	49409-0050 (315804)	

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
LAB	68 *	VENEGAS, et al., "Purification and Immunochemical Characterization of Ascitic Fluid Glycoproteins Containing Certain Tumor-Associated and Blood Group Antigen Markers", <i>Glycoconjugate Journal</i> , 1989, Vol. 6, pp. 511-524.	
	69 *	VOET et al., <i>Biochemistry</i> , 1990, pp. 1096 and 1098	
	70 *	VOET et al., <i>Biochemistry</i> , 1990, p. 78	
	71 *	VOLKMANN, M., et al., "Anti-p53 autoantibodies as serological marker in different tumor-entities", <i>Clinical Chemistry</i> , Volume 41, no. S6 part 2, 1995, pp. S221-S222	
	72 *	Abstract of VON MENS DORF-POUILLY et al.; <i>Anticancer Research</i> , Nov-Dec. 1997, Vol. 17, page 4184	
	73 *	VON MENS DORFF-POUILLY, S., "Humoral Immune Response to Polymorphic Epithelial Mucin (MUC-1) in patients with Benign and Malignant Breast Tumours"; <i>European Journal of Cancer</i> , Vol. 32A, No. 8, pp. 1325-1331, 1996	
	74 *	WOLF, et al., "A Tumour-Associated Antigen from The Pleural Effusion of Patients with Squamous-Cell Carcinoma of Lung", <i>Br. J. Cancer</i> , 1978, Vol. 36, pp. 1046-1052.	
	75 *	Abstract of YAMAMOTO et al.; <i>Proc. Amer. Soc. Cancer Res.</i> , March 1997, page 564	
	76 *	YAMAMOTO et al., "L-Myc Overexpression and Detection of Auto-Antibodies Against L-Myc in Both the Serum and Pleural Effusion from a Patient with Non-Small Cell Lung Cancer", <i>Internal Medicine</i> , 1997, Vol. 36, No. 10, pp. 724-727.	
	77 *	YAMAUCHI, et al., "Autoantibodies to C-MYC Nuclear Protein Products in Autoimmune Disease", 1989, pp. 117-119	
	78 *	ZISMAN et al.; <i>Journal of Urology</i> , 1995, Vol. 154, pp. 1052-1055	
	79 *	Definition of "monocyte" in On-line Medical Dictionary downloaded on 2/5/05 from url.cancerweb.ncl.ac.uk	

Examiner Signature	/Lynn Bristol/	Date Considered	03/27/2007
--------------------	----------------	-----------------	------------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.